The Impact of HFHD on Calcium-Phosphorus Metabolism and Nutritional Indicators in Patients with Chronic Kidney Disease

¹ Yangzhou University Medical College, Yangzhou 225000, Jiangsu, China; Department of Nephrology, Yangzhou Hongquan Hospital, Yangzhou 225200, Jiangsu, China,

² Department of Nephrology, Yangzhou Hongquan Hospital, Yangzhou 225200, Jiangsu, China,

³ Department of Nephrology, Northern Jiangsu People’s Hospital, Yangzhou 225000, Jiangsu, China,

JCNR 2026 , 10(3), 34–41; https://doi.org/10.26689/jcnr.v10i3.14485

© 2026 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Objective: To analyze the effects of high-flux hemodialysis (HFHD) on calcium and phosphorus metabolism and nutritional indicators in patients with chronic kidney disease (CKD). Methods: A total of 86 CKD patients diagnosed in our hospital’s Nephrology Department between January 2024 and December 2025 and undergoing HFHD were enrolled. Using a random number table, all patients were divided into a control group (n = 43, receiving conventional hemodialysis) and a study group (n = 43, receiving HFHD). SPSS 26.0 statistical software was used to compare calcium-phosphorus metabolism and nutritional indicators between the two groups. Results: After 6 months of treatment, the PTH level in the study group was significantly lower than that in the control group, while serum calcium and phosphorus levels were significantly higher (p < 0.05). The Alb and Hb levels in the study group were higher than those in the control group, but the difference was not statistically significant (p > 0.05). Conclusion: HFHD maintains calcium-phosphorus metabolism balance in CKD patients while significantly improving nutritional indicators.

References

Wang Y, Chen W, Liu W, et al., 2025, Prognosis of Fermented Cordyceps Powder Treatment in Patients with Stage 4 Chronic Kidney Disease: Findings from a Retrospective Cohort Study. Chinese General Practice, 28(9): 1084–1091.

Yang C, Zhang L, Zhao M, 2023, Interpretation of the Chinese Guidelines for Early Evaluation and Management of Chronic Kidney Disease. Chinese Journal of Practical Internal Medicine, 43(10): 839–841 + 876.

Wang J, 2025, Comparative Efficacy of Continuous Ambulatory Peritoneal Dialysis Versus Low-Flux Haemodialysis in End-Stage Renal Disease Patients. Doctor, 10(24): 141–144.

Chen A, Liu A, Li H, et al., 2025, Clinical Observation of High-Flux Haemodialysis in the Treatment of End-Stage Renal Disease. China Science and Technology Journal Database: Medicine, 2025(9): 78–81.

Yang K, Sun Y, Zhou Y, 2025, A Study on Dialysis Adequacy with Hemodiafiltration Combined with High-Flux Hemodialysis. Chinese Science & Technology Journal Database (Citation Edition) Medicine & Health, 2025(9): 153–156.

Gao X, Mei C, 2022, Interpretation of the Guidelines for Early Screening, Diagnosis and Prevention of Chronic Kidney Disease (2022 Edition). Chinese Journal of Practical Internal Medicine, 42(9): 735–739.

Liu Q, Xu Q, Zheng H, et al., 2025, Meta-Analysis and Pharmacoeconomic Evaluation of Valsartan Treatment for Chronic Kidney Disease with Hypertension. Chinese Journal of Modern Applied Pharmacy, 42(1): 124–129.

Dai Z, Li G, Zhai X, et al., 2025, Therapeutic Observation of Colon Dialysis Combined with Chinese Herbal Retention Enema in Patients with Chronic Kidney Disease Stages 3b–4. Chinese Prescription Drugs, 23(1): 98–101.

Liu X, Mao F, Chen Y, et al., 2025, Effectiveness and Prognostic Impact of High-Flux Haemodialysis Combined with Different Frequencies of Hemodiafiltration in Uremic Patients. Medical Theory and Practice, 38(10): 1695–1697 + 1723.

Wen X, Kuang G, Zhou Y, 2025, Application Value and Infection Risk of High-Flux Haemodialysis in Patients Undergoing Maintenance Haemodialysis. Chinese Journal of Practical Medicine, 20(1): 45–49.

Luo L, 2025, Clinical Efficacy Analysis of High-Flux Haemodialysis in Treating Chronic Kidney Disease. Chinese Journal of Community Physician, 41(15): 58–60.

Hu Y, Zhou X, Ying C, 2025, Safety of High-Flux Haemodialysis in the Treatment of Chronic Kidney Disease Patients. Dialysis and Artificial Organs, 36(2): 25–28.

Wang Z, Chai M, 2025, Clinical Efficacy of Jianspibixue Tablets Combined with High-Flux Haemodialysis in Treating End-Stage Renal Disease and Its Effects on Microinflammation Status and Renal Function. Tianjin Journal of Traditional Chinese Medicine, 42(6): 714–718.

Wang J, Kang R, 2025, Investigation into the Efficacy and Safety of Rosuvastatin Combined with High-Flux Haemodialysis in Patients with Chronic Kidney Disease. Chinese Journal of Modern Drug Application, 19(11): 127–130.

Armani G, Carvalho B, Silva E, et al., 2024, Effect of Haemodialysis with Medium Cut-Off vs High-Flux Membranes on Endothelial Function in Patients with Chronic Kidney Disease. Blood Purification, 53(7): 565–573.

Tang X, 2025, Clinical Efficacy of High-Flux Haemodialysis in End-Stage Renal Disease Patients. Systems Medicine, 10(8): 83–85.

Jia Y, Li G, 2025, Efficacy and Impact on Toxin Indicators of Sequential High-Flux Haemodialysis Combined with Hemodiafiltration in Chronic Renal Failure. System Medicine, 10(13): 100–102 + 106.

Chen W, 2025, Effects of Yishen Xie Zhuo Decoction Retention Enema Combined with High-Flux Haemodialysis on Calcium-Phosphorus Metabolism and Nutritional Indicators in Patients with Hyperphosphataemia Due to Chronic Kidney Disease. Reflex Therapy and Rehabilitation Medicine, 6(1): 20–23.

Previous article in this issue

Next article in this issue